<DOC>
	<DOC>NCT01174732</DOC>
	<brief_summary>This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of A006, from a select dose-range for future clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy, adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to Screening.</brief_summary>
	<brief_title>Dose-Ranging Study of A006 DPI, in Adult Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>With mildtomoderate persistent asthma for at least 6 months and having used inhaled betaagonist for asthma control; Must demonstrate response to beta 2 agonist by Reversing; Must demonstrate ability to use DPI; Females of childbearing potential must be nonpregnant, nonlactating, and practicing a clinically acceptable form of birth control; Additional Criteria Smoking history of ≥ 10 packyears, or having smoked within 6 months; Upper respiratory tract infections Asthma exacerbations; Known intolerance or hypersensitivity to any of the ingredients of the study drug or Proventil®; Use of prohibited drugs or failure to observe the drug washout restrictions; Having been on other clinical drug/device studies in the last 30 days; Other Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchospasm</keyword>
	<keyword>COPD</keyword>
	<keyword>chronic respiratory disease</keyword>
</DOC>